Press release

August 2017

Sorrento Therapeutics’ Pain Subsidiary, SCILEX Pharmaceuticals, Announces Positive Data from Head to Head Adhesion Study with its Lead Product, ZTlido™

August 31, 2017

– ZTlido™ demonstrated superior adhesion as compared to the reference product in the EU SAN DIEGO, June 14, 2017 /PRNewswire/ — SCILEX Pharmaceuticals Inc. (“SCILEX”), a subsidiary of Sorrento Therapeutics, Inc. (NASDAQ: SRNE, “Sorrento”) today announced that its lead investigational product, ZTlido™ (lidocaine medicated plaster 1.8%), has demonstrated superior adhesion versus the EU reference product Versatis® … Continue reading Sorrento Therapeutics’ Pain Subsidiary, SCILEX Pharmaceuticals, Announces Positive Data from Head to Head Adhesion Study with its Lead Product, ZTlido™

Sorrento Therapeutics, Inc. Submits NDA For ZTlido™ Next-Generation Lidocaine Patch

August 30, 2017

SAN DIEGO, Aug. 29, 2017 /PRNewswire/ — Sorrento Therapeutics, Inc. (NASDAQ: SRNE) (“Sorrento”), announced today that SCILEX Pharmaceuticals Inc. (“SCILEX”), a majority-owned subsidiary of Sorrento, resubmitted the NDA and responded to all of FDA comments related to the initial NDA submission for its lead product candidate, ZTlido™ (lidocaine patch 1.8%).  ZTlido is a next-generation non-opioid, … Continue reading Sorrento Therapeutics, Inc. Submits NDA For ZTlido™ Next-Generation Lidocaine Patch
X

Share This Page

XS SM MD LG XL